ViewRay has announced that the National Cancer Center Hospital (NCCH) of Japan has enhanced its original Cobalt MRIdian MRI-Guided Radiation Therapy System to the MRIdian Linac System and also treated its first patients.

Now NCCH can cater to cancer patients who are looking for personalised treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers with the MRIdian system.

In September 2016, NCC bought its first MRIdian System following the Japanese Ministry of Health, Labour and Welfare’s (MHLW) Shonin approval of the cobalt system the before month.

MRIdian Linac has linear accelerator delivery and allows everyday on-table adaptive radiotherapy and real-time tracking to regulate radiation beam delivery vigorously for subtle anatomical changes that may happen, during treatment delivery as well as throughout the course of treatment.

Combined, these skills help clinicians improve aiming accuracy and therefore deliver higher radiation doses.

National Cancer Center Hospital director Dr Kazuaki Shimada said: “Over the past six years we’ve seen firsthand the benefits of real-time MRI-guidance and on-table adaptive treatment delivery and its value in improving outcomes for cancer patients, so we look forward to incorporating the MRIdian Linac system to further enhance our MRI-guided radiation therapy offerings.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The MRIdian system offers oncologists anatomical visualisation via diagnostic-quality MR images and allows to adapt a radiation therapy plan to the targeted cancer with the patient on the table.

With this combination, physicians can describe tight treatment margins to evade needless radiation exposure to vulnerable organs at risk and healthy tissue.

This allows the delivery of ablative radiation doses in five or fewer treatment sessions, without trusting on fixed markers.

MRIdian offers real-time tracking of the aim and organs at risk and allows automatic gating of the radiation beam if the aim moves outside the user-defined margins.

With MRIdian almost 25,000 patients have been treated. At present, 53 systems are fitted at hospitals throughout the globe.